Mirvetuximab

Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα) -targeting ADC (Mirvetuximab soravtansine) . Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research[1][2][3].

Product Specifications

CAS Number

[1453084-36-0]

Product Name Alternative

M9346A

UNSPSC

12352203

Target

ADC Antibody; Antifolate

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mirvetuximab.html

Purity

99.88

Solubility

10 mM in DMSO

Smiles

[Mirvetuximab]

Molecular Weight

(145.2 kDa)

References & Citations

[1]Moore KN, et al. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 1;35 (10) :1112-1118.|[2]Loebrich S, et al. Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. AAPS J. 2017 Jul;19 (4) :1223-1234.|[3]Ab O, et al. IMGN853, a Folate Receptor-α (FRα) -Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. Mol Cancer Ther. 2015 Jul;14 (7) :1605-13.